• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?

作者信息

Licinio Raffaele, Facciorusso Antonio, Castellaneta Nicola Maurizio, Di Leo Alfredo

机构信息

Gastroenterology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.

Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy.

出版信息

Am J Gastroenterol. 2015 Jul;110(7):1086. doi: 10.1038/ajg.2015.163.

DOI:10.1038/ajg.2015.163
PMID:26148263
Abstract
摘要

相似文献

1
Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases?熊去氧胆酸与苯扎贝特联合治疗原发性胆汁性肝硬化患者：自身免疫性肝病类固醇时代的终结？
Am J Gastroenterol. 2015 Jul;110(7):1086. doi: 10.1038/ajg.2015.163.
2
Response to Licinio et al.对利西尼奥等人的回应
Am J Gastroenterol. 2015 Jul;110(7):1086-7. doi: 10.1038/ajg.2015.166.
3
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.熊去氧胆酸联合苯扎贝特治疗原发性胆汁性肝硬化伴血脂异常的前瞻性随机对照研究。
Am J Gastroenterol. 2015 Mar;110(3):423-31. doi: 10.1038/ajg.2015.20. Epub 2015 Mar 3.
4
Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.非诺贝特与苯扎贝特相比对无症状原发性胆汁性肝硬化患者的疗效。
Fukuoka Igaku Zasshi. 2013 Oct;104(10):350-61.
5
Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.
Am J Gastroenterol. 2000 Oct;95(10):2990-2. doi: 10.1111/j.1572-0241.2000.03220.x.
6
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.苯扎贝特治疗原发性胆汁性胆管炎的安慰剂对照试验。
N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.
7
Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study.苯扎贝特与熊去氧胆酸联合治疗原发性胆汁性肝硬化的初步研究。
Am J Gastroenterol. 2000 Jan;95(1):326-7. doi: 10.1111/j.1572-0241.2000.01667.x.
8
Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.对于对熊去氧胆酸反应不完全的原发性胆汁性肝硬化患者，苯扎贝特可使碱性磷酸酶恢复正常。
Liver Int. 2014 Feb;34(2):197-203. doi: 10.1111/liv.12290. Epub 2013 Sep 2.
9
Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.熊去氧胆酸治疗原发性胆汁性肝硬化应答不完全后应用苯扎贝特治疗。
J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.
10
[Bezafibrate for primary biliary cholangitis : Bezafibrate in combination with ursodeoxycholic acid in primary biliary cholangitis (BEZURSO) trial].[苯扎贝特用于原发性胆汁性胆管炎：苯扎贝特联合熊去氧胆酸治疗原发性胆汁性胆管炎（BEZURSO）试验]
Internist (Berl). 2018 Dec;59(12):1344-1346. doi: 10.1007/s00108-018-0515-1.

引用本文的文献

1
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.原发性胆汁性胆管炎的药物干预：一项网状Meta分析尝试
Cochrane Database Syst Rev. 2017 Mar 28;3(3):CD011648. doi: 10.1002/14651858.CD011648.pub2.
2
Response to Licinio et al.对利西尼奥等人的回应
Am J Gastroenterol. 2015 Jul;110(7):1086-7. doi: 10.1038/ajg.2015.166.

本文引用的文献

1
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.熊去氧胆酸联合苯扎贝特治疗原发性胆汁性肝硬化伴血脂异常的前瞻性随机对照研究。
Am J Gastroenterol. 2015 Mar;110(3):423-31. doi: 10.1038/ajg.2015.20. Epub 2015 Mar 3.
2
Oral budesonide for maintenance of remission of Crohn's disease: a pooled safety analysis.口服布地奈德维持克罗恩病缓解：一项汇总安全性分析
Aliment Pharmacol Ther. 2009 Mar 15;29(6):643-53. doi: 10.1111/j.1365-2036.2008.03891.x. Epub 2008 Nov 13.
3
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.
布地奈德在原发性胆汁性肝硬化中的药代动力学及对骨骼的影响
Aliment Pharmacol Ther. 2006 Dec;24(11-12):1545-52. doi: 10.1111/j.1365-2036.2006.03155.x.
4
Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.高胆固醇血症与原发性胆汁性肝硬化的早期动脉粥样硬化病变无关。
Gut. 2006 Dec;55(12):1795-800. doi: 10.1136/gut.2005.079814. Epub 2006 Apr 21.
5
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.熊去氧胆酸治疗对原发性胆汁性肝硬化自然病程的影响。
Gastroenterology. 2005 Feb;128(2):297-303. doi: 10.1053/j.gastro.2004.11.009.
6
Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial.口服布地奈德和熊去氧胆酸治疗原发性胆汁性肝硬化：一项前瞻性双盲试验的结果。
Gastroenterology. 1999 Oct;117(4):918-25. doi: 10.1016/s0016-5085(99)70351-3.